At TERMIS-AP 2025, the possibility of our technology being used to treat myocardial infarction was mentioned.
The artificial dura mater “DuraBeam®” will be exhibited at the 84th Annual Meeting of the Japan Neurosurgical Society (Wednesday, October 29th, 2025 – Saturday, November 1st, 2025).
We will be exhibiting the artificial pericardium prosthesis “PeriBeam®” at The 78th Annual Scientific Meeting of the Japanese Association for Thoracic Surgery (2025) (Thursday, October 23rd to Saturday, October 25th, 2025).
TamaBio will be sponsoring the 36th Japanese Society of Diencephalo-Pituitary Tumors (Thursday, March 5th and Friday, March 6th, 2026, Fukuoka City, Japan).
TamaBio has received a notice of grant decision for subsidy to support the international patent application for our domestic joint patent inventions with Tohoku University [Regenerative Medical Devices – Brain Tissue etc. Damage Repair Sheet].
TamaBio will be sponsoring the 57th Spine Surgery Club Meeting to be held on Aug.23rd at Nagasaki.
Nippon Medical School and TamaBio Sign New Joint Research Agreement : Regenerative Therapy for Infarcted Myocardium Using Epicardial Approach
Tamabio Co., Ltd. opened an account on “X”.
Biocompatibility and Tissue Regeneration Ability of the artificial dura mater DuraBeam was presented at CNTT2025/JSAN2025, Osaka International Convention Center
